- Report
- March 2024
- 195 Pages
Global
From €3262EUR$3,374USD£2,804GBP
€3624EUR$3,749USD£3,115GBP
- Report
- June 2023
- 150 Pages
Global
From €5752EUR$5,950USD£4,944GBP
- Report
- February 2024
- 175 Pages
Global
From €4834EUR$5,000USD£4,155GBP
- Report
- April 2024
- 179 Pages
Global
From €4785EUR$4,950USD£4,113GBP
- Report
- August 2023
- 180 Pages
Global
From €3625EUR$3,750USD£3,116GBP
- Report
- March 2024
- 200 Pages
Global
From €4012EUR$4,150USD£3,448GBP
- Report
- May 2023
- 153 Pages
Global
From €2417EUR$2,500USD£2,077GBP
- Report
- January 2024
- 150 Pages
Global
€4829EUR$4,995USD£4,150GBP
- Report
- July 2023
- 78 Pages
United States
From €3384EUR$3,500USD£2,908GBP
- Report
- November 2023
- 321 Pages
Global
From €4057EUR$4,197USD£3,487GBP
- Report
- March 2024
- 360 Pages
China, Global
From €4157EUR$4,300USD£3,573GBP
- Report
- September 2023
- 138 Pages
Global
From €3079EUR$3,185USD£2,646GBP
€4399EUR$4,550USD£3,781GBP
- Clinical Trials
- April 2024
- 200 Pages
Global
From €3384EUR$3,500USD£2,908GBP
- Drug Pipelines
- April 2024
- 550 Pages
Global
From €4834EUR$5,000USD£4,155GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1933EUR$2,000USD£1,662GBP
- Clinical Trials
- January 2024
- 60 Pages
Global
From €2900EUR$3,000USD£2,493GBP
- Report
- April 2024
- 256 Pages
Global
From €6762EUR$6,995USD£5,812GBP
- Report
- August 2023
- 267 Pages
Global
From €2150EUR$2,382USD£1,913GBP
- Report
- October 2023
- 420 Pages
Global
From €2803EUR$2,900USD£2,410GBP
- Report
- December 2023
- 220 Pages
Global
From €3190EUR$3,300USD£2,742GBP
Car T therapies are a type of immunotherapy used to treat certain types of cancer. They involve the use of genetically modified T cells, which are a type of white blood cell, to recognize and attack cancer cells. The T cells are taken from the patient's blood, modified in a laboratory, and then infused back into the patient's body. This type of therapy has been used to treat certain types of leukemia and lymphoma, and is being studied for use in other types of cancer.
Car T therapies are a relatively new type of oncology drug, and the market is still in its early stages. However, the potential of this type of therapy has led to a surge of interest from pharmaceutical companies, investors, and researchers. Companies are investing in research and development to improve the safety and efficacy of these therapies, as well as to expand their use to other types of cancer.
Some of the companies in the Car T therapies market include Novartis, Kite Pharma, Gilead Sciences, Juno Therapeutics, and Celgene. Show Less Read more